Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CELESTE trial of subretinal AAVB-039 for Stargardt disease
2025-522207-15-01Phase 2Authorised
- Sponsor
- AAVantgarde Bio
- Start
- Sep 2026
- Modality
- Gene Therapies
- Countries
- 6
01
Overview
Phase 2, open-label trial of AAVB-039 in Fundus Flavimaculatus (FF) (3 arms), sponsored by AAVantgarde Bio. Primary endpoint: Treatment-related adverse events. Planned start Sep 2026; status: authorised.
02
Drugs
AAVB-039
03
Conditions
Fundus Flavimaculatus (FF)
Beyond the preview
Go deeper on 2025-522207-15-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522207-15-01.